Livzon Pharmaceutical updates on A-share repurchase program

Livzon Pharmaceutical Group announced the continued implementation of its A-share repurchase program, which commenced following approvals in late 2024 and early 2025. As of October 31, 2025, the company had repurchased a total of 15,376,845 A-shares through centralized bidding on the Shenzhen Stock Exchange. These repurchases account for 1.70% of the company's total share capital.

The repurchases were executed at prices ranging from RMB 33.21 to RMB 41.99 per share, with the total capital expended amounting to RMB 570,228,471.25, excluding transaction fees. The company's disclosure reports indicate that the repurchased A-shares are intended for cancellation to reduce registered capital. As of October 31, 2025, no H-shares had been repurchased under the general mandate.

On November 3, 2025, Livzon Pharmaceutical Group repurchased an additional 164,000 A-shares on the Shenzhen Stock Exchange. These shares were acquired at prices between RMB 36.34 and RMB 36.7, with a total cost of RMB 5,996,902. The company confirmed that all repurchases comply with relevant regulatory requirements.